Disc Medicine (IRON) Expected to Announce Earnings on Thursday

Key Points

• Disc Medicine (NASDAQ:IRON) is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($1.17) per share.
• The company's stock recently opened at $59.00 and has seen a 52-week low of $30.82 and a high of $68.73, currently holding a market cap of $2.04 billion.
• Insider trading activity includes CEO John D. Quisel selling 34,800 shares at an average price of $55.33, resulting in a significant decrease of 17.70% in his ownership stake.

Disc Medicine (NASDAQ:IRON - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($1.17) per share for the quarter.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.41). On average, analysts expect Disc Medicine to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Disc Medicine Trading Up 1.7%

Disc Medicine stock traded up $0.96 during trading on Friday, hitting $58.03. The company's stock had a trading volume of 274,640 shares, compared to its average volume of 366,514. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -12.98 and a beta of 0.77. The stock's fifty day moving average is $55.01 and its 200 day moving average is $51.40. Disc Medicine has a 1-year low of $30.82 and a 1-year high of $68.73. The company has a debt-to-equity ratio of 0.04, a quick ratio of 37.65 and a current ratio of 37.65.

Insiders Place Their Bets

In related news, CFO Jean M. Franchi sold 2,031 shares of the stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $59.00, for a total value of $119,829.00. Following the completion of the transaction, the chief financial officer owned 63,499 shares of the company's stock, valued at approximately $3,746,441. This represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO John D. Quisel sold 34,800 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $55.33, for a total value of $1,925,484.00. Following the completion of the transaction, the chief executive officer directly owned 161,828 shares of the company's stock, valued at $8,953,943.24. This represents a 17.70% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 108,125 shares of company stock worth $6,234,626. Company insiders own 4.24% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IRON. Millennium Management LLC lifted its holdings in Disc Medicine by 1,277.1% during the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company's stock worth $5,386,000 after buying an additional 100,620 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Disc Medicine by 3.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company's stock worth $4,793,000 after purchasing an additional 3,454 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Disc Medicine by 22.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company's stock worth $756,000 after purchasing an additional 2,807 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on IRON shares. BMO Capital Markets upped their price target on Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a research note on Monday, May 12th. Wedbush reaffirmed an "outperform" rating and issued a $90.00 target price on shares of Disc Medicine in a research report on Monday, July 21st. Truist Financial assumed coverage on Disc Medicine in a research report on Monday, July 21st. They issued a "buy" rating and a $86.00 target price for the company. Raymond James Financial assumed coverage on Disc Medicine in a research report on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 target price for the company. Finally, Morgan Stanley assumed coverage on Disc Medicine in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $85.00 target price for the company. Eleven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $95.73.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.